• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Sprycel (dasatinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sprycel (dasatinib)

  • Profile

Profile

Contact Information

Contact: Bristol-Myers Squibb
Website: http://www.sprycel.com/

Currently Enrolling Trials

    Show More

    General Information

    Sprycel is a multiply-targeted tyrosine kinase inhibitor. Tyrosine kinases affect systems of cellular division and survival and are frequently over-expressed or abnormally active in cancer cells. By targeting these systems, Sprycel is designed to reduce the growth and viability of various types of cancer.

    Sprycel is specifically indicated to treat adults with chronic, accelerated, myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib. It is also indicated for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

    Mechanism of Action

    Sprycel is believed to bind to multiple conformations of ABL kinase. It has been shown to inhibit multiple tyrosine kinases at nanomolar concentrations, including BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRB.

    Side Effects

    Adverse events associated with the use of Sprycel may include, but are not limited to, the following:

    • hemorrhage (including gastrointestinal bleeding)
    • fluid retention (including pleural effusion)
    • febrile neutropenia
    • infection
    • dyspnea
    • pneumonia
    • pyrexia
    • diarrhea
    • headache
    • musculoskeletal pain

    Myelosuppression was commonly reported, including serious or severe neutropenia, thrombocytopenia and anemia. The rate of myelosuppression was higher in patients with accelerated phase or myeloid blast phase CML or lymphoid blast phase Ph+ ALL than in patients with chronic phase CML.

    The effectiveness of Sprycel may be affected by concomitant administration of other drugs:

    • Sprycel is metabolized by the liver enzyme CYP3A4. Drugs which inhibit this enzyme (including but not limited to ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may affect the pharmacokinetics of Sprycel and increase acute drug exposure. Concomitant administration of these medications should be avoided.
    • Drugs which induce increased expression of CYP3A4 (including but not limited to dexamethasone, phenytoin, carbamazepine, rifampicin and phenobarbital) may reduce levels of Sprycel. Alternative therapies and/or dose Sprycel dose adjustment is recommended.
    • St. John's wort has been shown to unpredictably decrease Sprycel plasma levels
    •  and should be avoided while on Sprycel therapy.
    • Sprycel's solubility is Ph dependent. As such, use of antacids within two hours before or after Sprycel administration is not recommended. Use of long-term acid reducers such as H2 blockers or proton pump inhibitors (including but not limited to famotidine or omeprazole) is not recommended while on Sprycel.

    Dosing/Administration

    Sprycel is supplied as a white to off-white, biconvex, film-coated tablet designed for oral administration. The recommended initial dosing of Sprycel is 70 mg twice daily with or without food. Incremental dose increase or decrease (in 20 mg steps) is recommended based on individual safety and tolerability.

    Clinical Trial Results

    Approval of Sprycel was based on four, single-arm, multicenter studies that investigated the safety and efficacy of the drug in treating imatinib-resistant or imatinib-intolerant CML and Ph+ ALL. In all four trials, subjects received 70 mg Sprycel twice daily. These trials were all ongoing at the time of approval. The four studies each investigated the drug in the treatment of a single disease subclass.

    Chronic phase CML study
    This trial enrolled 186 patients with imatinib resistant (68 percent) or intolerant (32 percent) chronic-phase CML. Subjects received treatment for a median of 5.6 months (range: 0.03 to 8.3 months). Results yielded efficacy in the trial's primary endpoint, with Sprycel producing major cytogenetic response (MCyR) in 45 percent of subjects, including complete cytogenic response (CCyR, defined as 0 percent Ph+ cells detected) in 33 percent of subjects. Further, complete hematologic response (CHR) was achieved in 90 percent of subjects.

    Accelerated phase CML study
    This trial enrolled 107 patients with imatinib resistant (93 percent) or intolerant (7 percent) accelerated-phase CML. Subjects received treatment for a median of 5.5 months (range: 0.2 to 10.1 months). Results yielded efficacy in the trial's primary endpoint, with Sprycel producing major hematologic response (MaHR) in 59 percent of subjects, including CHR in 33 percent of subjects and no evidence of leukemia (NEL) in 26 percent of subjects. In addition, MCyR was achieved in 31 percent of subjects, including CCyR in 21 percent of subjects.

    Myeloid blast phase CML study
    This trial enrolled 74 patients with imatinib resistant (92 percent) or intolerant (8 percent) myeloid-blast-phase CML. Subjects received treatment for a median of 3.5 months (range: 0.03 to 9.2 months). Results yielded efficacy in the trial's primary endpoint, with Sprycel producing MaHR in 32 percent of subjects, including CHR in 24 percent of subjects and NEL in 8 percent of subjects. In addition, MCyR was achieved in 30 percent of subjects, including CCyR in 27 percent of subjects.

    Lymphoid blast phase CML/Ph+ ALL study
    This trial enrolled 42 patients with imatinib resistant (92 percent) or intolerant (8 percent) lymphoid-blast-phase CML, and 36 patients with imatinib resistant (94 percent) or intolerant (6 percent) Ph+ ALL. CML subjects received treatment for a median of 2.8 months (range: 0.1 to 6.4 months) and Ph+ ALL subjects received treatment for a median of 3.2 months (range: 0.2 to 8.1 months). Results yielded efficacy in the trial's primary endpoint, with Sprycel producing MaHR in 31 percent of CML subjects and 42 percent of Ph+ ALL subjects, including CHR in 26 percent and 31 percent of subjects and NEL in 5 percent and 11 percent of subjects, respectively. In addition, MCyR was achieved in 50 percent and 58 percent of subjects, including CCyR in 58 percent and 58 percent of subjects.

    Approval Date: 2006-06-01
    Company Name: Bristol-Myers Squibb
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing